News

Results Found (485)
August 8, 2007
Yissum and Protalix BioTherapeutics Sign Agreement to License...

Protalix BioTherapeutics, Inc. , today announced it has signed an agreement with the Yissum Research and Development Company, the technology transfer arm of the Hebrew University of Jerusalem, Israel, and the Boyce Thompson Institute for Plant...

August 1, 2007
Hebrew U.'s Yissum teams with Neocrine Biosciences

Neocrine Biosciences Inc. will develop valnoctamide, which has potential for treating neurological and psychiatric disorders discovered at Hebrew University.

July 26, 2007
Virtual eternal life is not science fiction but rather a technological...

Prof. Naftali Tishby dreams of the day when we will be able transfer a copy of our souls onto the computer before our death so that the soul will continue to think, feel, and answer our grandchildren's questions long after our bodies...

July 25, 2007
Yissum spin-off Novagali Pharma files prospectus for Euronext IPO

The French-Israeli eye drug maker uses technology developed by the Hebrew University of Jerusalem.

July 3, 2007
Merck reinventing itself- an interview with Dr. Strulovici, Merck's VP for...

Merck shopping for new technologies for the improvement of drug development 

June 24, 2007
BioJerusalem Launches Activities

Jerusalem Development Authority allocates initial 10 million NIS to BioJerusalem

June 21, 2007
Yissum spin-off Mobileye - a warning system as your co-pilot

Reinventing the wheel- the latest car technology on the Wall Street Journal

June 6, 2007
Chilean president's first cousin shares prestigious HU young researcher award

A Hebrew University doctoral student who is the first cousin of the president of Chile has won a prestigious research prize for developing a "knockout technique" in special "antibody nose drops" against allergies that he tested successfully on...

May 24, 2007
Through the Glass Ceiling: Professional and positive- A profile of Nava...

Nava Swersky Sofer isn't the type of person to look back at her accomplishments and congratulate herself. Instead, she says, she's a forward thinker who focuses keenly on her next move. 

April 17, 2007
Yissum spin-off Tiltan knocks cancer to it knees (Hebrew article)

Tiltan attacks cancer using four different materials 

 

April 12, 2007
Yissum Subsidiary Collplant raises NIS 18.6m

The company has developed a method for applying transgenic tobacco to produce human recombinant collagen.

April 11, 2007
Yissum sells its Holdings in BioCancell Theraputics to Clal Biotechnology...

CBI will purchase 24% of the cancer-drug developer; Yissum keeps its royalties agreement